ALIVUS — Alivus Life Sciences Cashflow Statement
0.000.00%
- IN₹126.99bn
- IN₹121.84bn
- IN₹22.83bn
- 94
- 21
- 70
- 69
Annual cashflow statement for Alivus Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | C2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 4,211 | 4,709 | 5,649 | 6,286 | 6,313 |
Depreciation | |||||
Non-Cash Items | 277 | 1,003 | 399 | 183 | 378 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2,832 | -2,166 | -451 | -3,830 | -3,091 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 1,950 | 3,881 | 5,976 | 3,060 | 4,135 |
Capital Expenditures | -512 | -680 | -1,322 | -1,628 | -1,290 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 6.48 | -7.41 | 99.4 | 161 | 125 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -505 | -687 | -1,222 | -1,467 | -1,165 |
Financing Cash Flow Items | — | — | -0.72 | -5.47 | -15.5 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -1,366 | -2,138 | -788 | -3,876 | -2,794 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 79.4 | 1,056 | 3,966 | -2,283 | 176 |